Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus paclitaxel in advanced gastric or gastroesophageal junction cancer
NCT06904300Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2025
- Primary completion
- Apr 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of ivonescimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06904300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904300.